The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
Open accessAbstract
Key Points: Weekly oral proteasome inhibitor ixazomib appears generally well tolerated with manageable toxicity, limited grade 1/2 neuropathy. Data show that more than 25% of 30 evaluable relapsed/refractory myeloma patients who received the MTD had clinically meaningful responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 5×
“Lymphopenia 3 (9) 3 (9) 5 (16) 3 (10) 7 (12) 5 (8)”
InfluentialSelf-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458
Kumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-395749 · Cited by 446
Self-citationEfficacy and safety of once-weekly bortezomib in multiple myeloma patients
Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., et al. (2010) · Blood · doi:10.1182/blood-2010-07-294983 · Cited by 381
Research works printed but not linked: 33
- Richardson, 2010, Tailoring treatment for multiple myeloma patients with relapsed and refractory disease., Oncology (Williston Park), 24, 22
- Kumar, 2009, Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines., Mayo Clin Proc, 84, 1095, 10.4065/mcp.2009.0603 · DOI · Paper page
- Gentile, 2012, Emerging biological insights and novel treatment strategies in multiple myeloma., Expert Opin Emerg Drugs, 17, 407, 10.1517/14728214.2012.713345 · DOI
- Anderson, 2012, The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma., J Clin Oncol, 30, 445, 10.1200/JCO.2011.37.8919 · DOI
- Anderson, 2013, Multiple myeloma, version 1.2013., J Natl Compr Canc Netw, 11, 11, 10.6004/jnccn.2013.0004 · DOI
- Kumar, 2008, Improved survival in multiple myeloma and the impact of novel therapies., Blood, 111, 2516, 10.1182/blood-2007-10-116129 · DOI · Paper page
- Brenner, 2008, Recent major improvement in long-term survival of younger patients with multiple myeloma., Blood, 111, 2521, 10.1182/blood-2007-08-104984 · DOI · Paper page
- Jagannath, 2009, Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma., Br J Haematol, 146, 619, 10.1111/j.1365-2141.2009.07803.x · DOI
- Cavo, 2010, Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study., Lancet, 376, 2075, 10.1016/S0140-6736(10)61424-9 · DOI · Paper page
- Sonneveld, 2012, Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial., J Clin Oncol, 30, 2946, 10.1200/JCO.2011.39.6820 · DOI · Paper page
- Richardson, 2005, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma., N Engl J Med, 352, 2487, 10.1056/NEJMoa043445 · DOI · Paper page
- Richardson, 2007, Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma., Br J Haematol, 137, 429, 10.1111/j.1365-2141.2007.06585.x · DOI
- Mikhael, 2009, High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program., Br J Haematol, 144, 169, 10.1111/j.1365-2141.2008.07409.x · DOI
- Richardson, 2010, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma., Blood, 116, 679, 10.1182/blood-2010-02-268862 · DOI · Paper page
- Jagannath, 2007, Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials., Leukemia, 21, 151, 10.1038/sj.leu.2404442 · DOI · Paper page
- Bergsagel, 2013, Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma., Blood, 121, 884, 10.1182/blood-2012-05-432203 · DOI · Paper page
- Rajkumar, 2013, Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management., Am J Hematol, 88, 226, 10.1002/ajh.23390 · DOI · Paper page
- Chanan-Khan, 2012, Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment., Clin Cancer Res, 18, 2145, 10.1158/1078-0432.CCR-11-0498 · DOI
- Dimopoulos, 2013, The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma., Leukemia, 27, 423, 10.1038/leu.2012.182 · DOI · Paper page
- Richardson, 2012, Management of treatment-emergent peripheral neuropathy in multiple myeloma., Leukemia, 26, 595, 10.1038/leu.2011.346 · DOI · Paper page
- Reeder, 2010, Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma., Blood, 115, 3416, 10.1182/blood-2010-02-271676 · DOI · Paper page
- Kupperman, 2010, Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer [published correction appears in Cancer Res. 2010;70(9):3853]., Cancer Res, 70, 1970, 10.1158/0008-5472.CAN-09-2766 · DOI · Paper page
- Chauhan, 2011, In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells., Clin Cancer Res, 17, 5311, 10.1158/1078-0432.CCR-11-0476 · DOI · Paper page
- Lee, 2011, Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies., Clin Cancer Res, 17, 7313, 10.1158/1078-0432.CCR-11-0636 · DOI
- Tian, 2012, Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells., Blood, 120, 3958, 10.1182/blood-2012-01-401794 · DOI · Paper page
- Siegel, 2012, A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma., Blood, 120, 2817, 10.1182/blood-2012-05-425934 · DOI · Paper page
- Vij, 2012, An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma., Blood, 119, 5661, 10.1182/blood-2012-03-414359 · DOI · Paper page
- Bladé, 1998, Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation., Br J Haematol, 102, 1115, 10.1046/j.1365-2141.1998.00930.x · DOI · Paper page
- Richardson, Phase 1 study of twice-weekly dosing of investigational oral proteasome inhibitor ixazomib in patients with relapsed and/or refractory multiple myeloma., Blood
- Kumar, 2012, A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM)., Blood, 120, 332, 10.1182/blood.V120.21.332.332 · DOI
- Lonial, 2005, Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma., Blood, 106, 3777, 10.1182/blood-2005-03-1173 · DOI · Paper page
- Lonial, 2008, Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma., Br J Haematol, 143, 222, 10.1111/j.1365-2141.2008.07321.x · DOI
- Jakubowiak, 2012, A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma., Blood, 120, 1801, 10.1182/blood-2012-04-422683 · DOI · Paper page
Cited by
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
“Muscle spasms 66 (18) 0 0 95 (26) 2 (<1) 0”
Self-citationProteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
The proteasome and proteasome inhibitors in multiple myeloma
Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9707-8 · Cited by 340
Rajkumar, S. V., Landgren, O., & Mateos, M.-V. (2015) · Blood · doi:10.1182/blood-2014-09-568899 · Cited by 269
Kumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M., Stewart, A. K., Hari, P., Roy, V., Vescio, R., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71125-8 · Cited by 262
Self-citation
Metadata
- Authors
- Kumar, S. K., Bensinger, W. I., Zimmerman, T. M., Reeder, C. B., Berenson, J. R., Berg, D., Hui, A.-M., Gupta, N., Di Bacco, A., Yu, J., Shou, Y., & Niesvizky, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-08-14
- Volume
- 124
- Issue
- 7
- Pages
- 1047-1055
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1979068418
- Cited by
- 197
- References
- 7
- FWCI
- 22.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2014-01-548941
- The paper
- Kumar, S. K., Bensinger, W. I., Zimmerman, T. M., Reeder, C. B., Berenson, J. R., Berg, D., Hui, A.-M., Gupta, N., Di Bacco, A., Yu, J., Shou, Y., & Niesvizky, R. (2014). Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2014-01-548941
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.